开云app官网登录入口网页版-官方正版

#ALK阳性#

66篇内容 | 1918人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2198769, encodeId=f0702198e6947, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a> <a href='/topic/show?id=be329e849f6' target=_blank style='color:#2F92EE;'>#阿来替尼#</a>, objectTitle=NEJM：阿来替尼在可切除ALK阳性NSCLC辅助治疗中展现显著疗效, objectType=article, longId=821750, objectId=c959821e50f7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240415/1713189527320_6145188.png, objectUrl=/article/show_article.do?id=c959821e50f7, replyNumber=0, likeNumber=107, createdTime=2024-04-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c959821e50f7, moduleTitle=NEJM：阿来替尼在可切除ALK阳性NSCLC辅助治疗中展现显著疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c959821e50f7)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1987565, encodeId=8426198e56516, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=J Thorac Oncol: Lorlatinib（劳拉替尼）治疗既往经治ALK阳性晚期或转移NSCLC中国患者的疗效, objectType=article, longId=301255, objectId=1a8d30125528, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a8d30125528, replyNumber=0, likeNumber=90, createdTime=2022-09-21, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a8d30125528, moduleTitle=J Thorac Oncol: Lorlatinib（劳拉替尼）治疗既往经治ALK阳性晚期或转移NSCLC中国患者的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1a8d30125528)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987566, encodeId=5b88198e56654, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS, objectType=article, longId=727788, objectId=2cfae27788c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cfae27788c8, replyNumber=0, likeNumber=85, createdTime=2023-04-12, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cfae27788c8, moduleTitle=J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2cfae27788c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987567, encodeId=162b198e56767, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=Thorac Cancer：ALK阳性晚期NSCLC患者克唑替尼进展后不同治疗模式的疗效, objectType=article, longId=727467, objectId=fe0ae2746739, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe0ae2746739, replyNumber=0, likeNumber=83, createdTime=2023-02-05, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe0ae2746739, moduleTitle=Thorac Cancer：ALK阳性晚期NSCLC患者克唑替尼进展后不同治疗模式的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fe0ae2746739)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987564, encodeId=f9ce198e564c4, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=Thorac Cancer：ALK阳性是I期完全切除的肺腺癌患者无复发生存期（RFS）负性预测指标, objectType=article, longId=300924, objectId=c0743009248b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0743009248b, replyNumber=0, likeNumber=100, createdTime=2022-11-08, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0743009248b, moduleTitle=Thorac Cancer：ALK阳性是I期完全切除的肺腺癌患者无复发生存期（RFS）负性预测指标, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c0743009248b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987560, encodeId=f104198e560d8, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效 , objectType=article, longId=217043, objectId=644421e04318, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=644421e04318, replyNumber=0, likeNumber=73, createdTime=2022-04-13, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=644421e04318, moduleTitle=J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效 , moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=644421e04318)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987559, encodeId=1758198e55992, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=JAMA Oncol：恩沙替尼vs克唑替尼治疗ALK阳性非小细胞肺癌的疗效：III期随机临床研究, objectType=article, longId=216851, objectId=7b11216851b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b11216851b9, replyNumber=0, likeNumber=70, createdTime=2021-09-29, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b11216851b9, moduleTitle=JAMA Oncol：恩沙替尼vs克唑替尼治疗ALK阳性非小细胞肺癌的疗效：III期随机临床研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7b11216851b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987563, encodeId=14ba198e56356, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=Thorac Cancer：克唑替尼-阿来替尼续贯方案治疗中国晚期ALK阳性NSCLC患者的疗效, objectType=article, longId=221572, objectId=bfd12215e24f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfd12215e24f, replyNumber=0, likeNumber=101, createdTime=2021-12-17, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfd12215e24f, moduleTitle=Thorac Cancer：克唑替尼-阿来替尼续贯方案治疗中国晚期ALK阳性NSCLC患者的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bfd12215e24f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987558, encodeId=7ddc198e55844, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=Cancer Sci：阿来替尼可有效且安全的治疗复发或难治的ALK阳性淋巴瘤, objectType=article, longId=212383, objectId=7fa221238379, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fa221238379, replyNumber=0, likeNumber=87, createdTime=2021-10-22, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fa221238379, moduleTitle=Cancer Sci：阿来替尼可有效且安全的治疗复发或难治的ALK阳性淋巴瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7fa221238379)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987561, encodeId=2a1b198e56102, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果, objectType=article, longId=217316, objectId=e44421e31653, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e44421e31653, replyNumber=0, likeNumber=66, createdTime=2022-08-21, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e44421e31653, moduleTitle=J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e44421e31653)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987562, encodeId=1cfc198e5625c, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=Front Oncol：贝叶斯网状Meta分析比较ALK阳性NSCLC患者一线治疗方案的疗效和安全性, objectType=article, longId=220334, objectId=0e9e2203349a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e9e2203349a, replyNumber=0, likeNumber=76, createdTime=2022-08-12, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e9e2203349a, moduleTitle=Front Oncol：贝叶斯网状Meta分析比较ALK阳性NSCLC患者一线治疗方案的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0e9e2203349a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987556, encodeId=4419198e55682, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=Ann Oncol：劳拉替尼用于二代TKI治疗过的ALK阳性NSCLC患者的颅内外疗效, objectType=article, longId=207814, objectId=aa0620e814a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa0620e814a1, replyNumber=0, likeNumber=92, createdTime=2021-05-17, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa0620e814a1, moduleTitle=Ann Oncol：劳拉替尼用于二代TKI治疗过的ALK阳性NSCLC患者的颅内外疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aa0620e814a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987553, encodeId=04ba198e55354, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼, objectType=article, longId=203570, objectId=632d2035e081, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=632d2035e081, replyNumber=0, likeNumber=82, createdTime=2021-07-18, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=632d2035e081, moduleTitle=NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=632d2035e081)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987555, encodeId=1c71198e555a5, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=FDA批准辉瑞ALK抑制剂克唑替尼新适应证：ALK阳性间变性大细胞淋巴瘤, objectType=article, longId=205805, objectId=fa1f20580549, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa1f20580549, replyNumber=0, likeNumber=75, createdTime=2021-09-28, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa1f20580549, moduleTitle=FDA批准辉瑞ALK抑制剂克唑替尼新适应证：ALK阳性间变性大细胞淋巴瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fa1f20580549)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987554, encodeId=9d6b198e554a5, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=LORBRENA（lorlatinib）治疗先前未经治疗的ALK阳性肺癌的sNDA已被美国FDA接受优先审查, objectType=article, longId=204976, objectId=72d72049e6db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72d72049e6db, replyNumber=0, likeNumber=89, createdTime=2021-09-11, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72d72049e6db, moduleTitle=LORBRENA（lorlatinib）治疗先前未经治疗的ALK阳性肺癌的sNDA已被美国FDA接受优先审查, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=72d72049e6db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987557, encodeId=c011198e5571f, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=优效于克唑替尼，FDA批准劳拉替尼一线治疗ALK阳性)阳性非小细胞肺癌(NSCLC)患者, objectType=article, longId=208126, objectId=a66d208126c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a66d208126c5, replyNumber=0, likeNumber=73, createdTime=2021-10-03, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a66d208126c5, moduleTitle=优效于克唑替尼，FDA批准劳拉替尼一线治疗ALK阳性)阳性非小细胞肺癌(NSCLC)患者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a66d208126c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987549, encodeId=9236198e549d6, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物, objectType=article, longId=191689, objectId=a505191689b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a505191689b3, replyNumber=0, likeNumber=76, createdTime=2020-06-11, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a505191689b3, moduleTitle=欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a505191689b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987552, encodeId=8b8c198e552b7, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=NEJM：用于晚期ALK阳性肺癌：劳拉替尼 or 克唑替尼, objectType=article, longId=203540, objectId=56b8203540c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56b8203540c9, replyNumber=0, likeNumber=78, createdTime=2021-01-07, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56b8203540c9, moduleTitle=NEJM：用于晚期ALK阳性肺癌：劳拉替尼 or 克唑替尼, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=56b8203540c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987551, encodeId=83e2198e5515f, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期, objectType=article, longId=198887, objectId=e4c319888efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4c319888efe, replyNumber=0, likeNumber=74, createdTime=2020-10-23, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4c319888efe, moduleTitle=肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e4c319888efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987546, encodeId=5c61198e546ff, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势, objectType=article, longId=183563, objectId=716c183563f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=716c183563f0, replyNumber=0, likeNumber=80, createdTime=2020-09-29, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=716c183563f0, moduleTitle=ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=716c183563f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

ALK阳性

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#NSCLC# #ALK阳性# #阿来替尼#

NEJM：阿来替尼在可切除ALK阳性NSCLC辅助治疗中展现显著疗效

2024-04-16发表于上海

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

J Thorac Oncol: Lorlatinib（劳拉替尼）治疗既往经治ALK阳性晚期或转移NSCLC中国患者的疗效

2022-09-21

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS

2023-04-12

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

Thorac Cancer：ALK阳性晚期NSCLC患者克唑替尼进展后不同治疗模式的疗效

2023-02-05

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

Thorac Cancer：ALK阳性是I期完全切除的肺腺癌患者无复发生存期（RFS）负性预测指标

2022-11-08

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效

2022-04-13

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

JAMA Oncol：恩沙替尼vs克唑替尼治疗ALK阳性非小细胞肺癌的疗效：III期随机临床研究

2021-09-29

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

Thorac Cancer：克唑替尼-阿来替尼续贯方案治疗中国晚期ALK阳性NSCLC患者的疗效

2021-12-17

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

Cancer Sci：阿来替尼可有效且安全的治疗复发或难治的ALK阳性淋巴瘤

2021-10-22

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果

2022-08-21

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

Front Oncol：贝叶斯网状Meta分析比较ALK阳性NSCLC患者一线治疗方案的疗效和安全性

2022-08-12

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

Ann Oncol：劳拉替尼用于二代TKI治疗过的ALK阳性NSCLC患者的颅内外疗效

2021-05-17

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

NEJM：“头对头”III期研究证实治疗ALK阳性非小细胞肺癌，劳拉替尼显著优于克唑替尼

2021-07-18

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

FDA批准辉瑞ALK抑制剂克唑替尼新适应证：ALK阳性间变性大细胞淋巴瘤

2021-09-28

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

LORBRENA（lorlatinib）治疗先前未经治疗的ALK阳性肺癌的sNDA已被美国FDA接受优先审查

2021-09-11

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

优效于克唑替尼，FDA批准劳拉替尼一线治疗ALK阳性)阳性非小细胞肺癌(NSCLC)患者

2021-10-03

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物

2020-06-11

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

NEJM：用于晚期ALK阳性肺癌：劳拉替尼 or 克唑替尼

2021-01-07

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期

2020-10-23

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势

2020-09-29

科室
- - 订阅+
  - 更多科室
工具
服务